These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28321144)

  • 1. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Klafehn CW
    Hosp Pharm; 2016 Sep; 51(8):688-691. PubMed ID: 27698510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rubio T
    Hosp Pharm; 2016 Mar; 51(3):268. PubMed ID: 38745575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries of safety labeling changes approved by FDA-Boxed Warnings Highlights October-December 2014.
    Rubio T
    Am J Health Syst Pharm; 2015 Mar; 72(5):343. PubMed ID: 25694404
    [No Abstract]   [Full Text] [Related]  

  • 10. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 12. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA boxed warnings: how to prescribe drugs safely.
    O'Connor NR
    Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Mar; 75(5):e113-e114. PubMed ID: 29472516
    [No Abstract]   [Full Text] [Related]  

  • 16. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Mar; 75(5):259. PubMed ID: 29472507
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2016.
    Am J Health Syst Pharm; 2017 Mar; 74(5):277-278. PubMed ID: 28213489
    [No Abstract]   [Full Text] [Related]  

  • 18. Summaries of Safety Labeling Changes Approved By FDA- Boxed Warnings Highlights October-December 2017.
    Hosp Pharm; 2018 Jun; 53(3):134-135. PubMed ID: 30147130
    [No Abstract]   [Full Text] [Related]  

  • 19. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2018.
    Am J Health Syst Pharm; 2019 Mar; 76(7):412. PubMed ID: 31361824
    [No Abstract]   [Full Text] [Related]  

  • 20. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.